Back to the main directory
Company Analysis / Equity
- Nouvelle étape dans sa quête de croissance- ACHAT - OBJECTIF : 56€ (vs 52€) by Invest Securities
- Prise de profit conseillée après le parcours 2017 - NEUTRE vs ACHAT - OBJECTIF : 76€ (vs 74€) by Invest Securities
- Un optimisme béat que nous ne partageons pas - VENTE vs NEUTRE - OBJECTIF : 34€ (vs 33€) by Invest Securities
- Le prélude à des opérations plus significatives ? - NEUTRE - OBJECTIF : 32€ (vs 30€) by Invest Securities
- T3 sans surprise, cas d’investissement inchangé - VENTE - OBJECTIF : 34€ by Invest Securities
- Stratégie inchangée malgré un T3 médiocre - NEUTRE, OC 14,7£ vs 15£ by Invest Securities
- International activities will drive growth - BUY - TP 5,8€ (vs 6€) by Invest Securities
- From the other side of the mirror… - HOLD - TP 18€ by Invest Securities
- Expanding product portfolio - BUY - TP 12,1€ by Invest Securities
- Secto? by Invest Securities
- De bons présages pour le développement - ACHAT - OC 6,6€ (vs 6,8€) by Invest Securities
- Toujours trop tôt pour devenir positif - NEUTRE - OC 23,5€ (vs 26€) by Invest Securities
- Dans le bon sens mais trop tôt pour devenir positifs - NEUTRE - OC 2-,5€ (vs 24€) by Invest Securities
- Spin off réfléchi et naturel : réussite potentielle ? - ACHAT - OC 34,1€ by Invest Securities
- La recovery des résultats 2016/2017 en marche ? - NEUTRE - OC 47€ by Invest Securities
- Réinvention de la marque Gucci : un cas d'école - ACHAT - OC 345€ (vs 265€) by Invest Securities
- TOBACCO SECTOR REPORT by Genghis Capital
- T.H. Data Flash - New Oriental Education & Technology – FY2Q18: Rapid Expansion Drives Growth of Courses, Attendees and Revenues in FY2Q18 by T.H. Capital
- Tanzania Cigarette Co by Genghis Capital
- Mutation accélérée vers les services de paiement - ACHAT, OC 110€ (vs 105€) by Invest Securities
- Investors Should Take Profits After California Resources' Run-Up by Morningstar
- XPO Logistics has evolved well beyond asset-light freight brokerage. by Morningstar
- Ancillary businesses distinguish Lennar from many other homebuilders. by Morningstar
- Despite regulatory and competitive challenges, Dr. Reddy looks better positioned for generics growth by Morningstar
- Tencent’s FVE Raised by 45% to HKD 492 (USD 63) After Coverage Transfer; Shares Undervalued by Morningstar
- Laissons-nous encore porter un moment - ACHAT - OBJECTIF : 74€ (vs 70€) by Invest Securities
- Un repli à mettre à profit- ACHAT - OBJECTIF : 64€ by Invest Securities
- Thèse d’investissement confortée - NEUTRE - OBJECTIF 30€ by Invest Securities
- Solide croissance, mais potentiel limité hors acquisition - NEUTRE - OBJECTIF : 22€ (vs 21€) by Invest Securities
- Synergies, le tube de l’été - NEUTRE - OBJECTIF : 33€ (vs 32€) by Invest Securities
- Le profit warning de trop - NEUTRE vs ACHAT, OC 15£ vs 19,9£ by Invest Securities
- Moving up the value chain - BUY - TP 4,8€ by Invest Securities
- Combining for better treatment - BUY - TP 14,3€ by Invest Securities
- "APA" for the big pharmas? - BUY - TP 8,8€ by Invest Securities
- Good signs for development - BUY - TP 6,6€ (vs 6,8€) by Invest Securities
- A specific pathway - BUY - TP 3€ by Invest Securities
- Un T4 correct qui va dans le bon sens - NEUTRE - OC 23,5€ by Invest Securities
- Beau, mais à la limite de la survalorisation - NEUTRE - OC 13,4€ by Invest Securities
- Que donner de plus au marché pour le satisfaire ? - ACHAT - OC 23,8€ by Invest Securities
- La dynamique de croissance jusqu'où ? - ACHAT - OC 260€ (vs 240€) by Invest Securities
- Egdon Resources - Wressle planning appeal rejected by Edison Investment Research
- e-Therapeutics - Nearing prime time validation by Edison Investment Research
- British American Tobacco Uganda by Genghis Capital
- With the help of tax reform, Charles Schwab's earnings should more than double in five years. by Morningstar
- Evolva - Capital restructuring by Edison Investment Research
- NVR's capital efficiency is best-in-class among public homebuilders. by Morningstar
- PulteGroup is well-positioned for growth in 2018. by Morningstar
- Despite regulatory and competitive challenges, Dr. Reddy looks better positioned for generics growth by Morningstar
- Despite regulatory and competitive challenges, Dr. Reddy looks better positioned for generics growth by Morningstar
- Lifting Sony’s FVE to JPY 4,600; While this Year’s Numbers Are Notable, Upside on Share Is Limited by Morningstar